Skip to main content.

Robert A. Montgomery

Expert Profile

Robert A. Montgomery

Director, Transplant Surgeon
Johns Hopkins Comprehensive Transplant Center


Robert A. Montgomery, MD, DPhil, is an Associate Professor of Surgery, Director of the Incompatible Kidney Transplant Program, Chief of the Division of Transplantation, and Director of the Comprehensive Transplant Center, at the Johns Hopkins University and Hospital. He received his Medical education at the University of Rochester where he was the valedictorian of his class. He received his PhD at the University of Oxford, England in molecular immunology. Montgomery completed his general surgical and multi-organ transplantation training at Johns Hopkins Hospital. He was a postdoctoral fellow in Human Molecular Genetics also at Johns Hopkins.

Dr. Montgomery has been involved in the development innovative approaches to expanding live donor renal transplantation including: the laparoscopic donor nephrectomy, positive crossmatch and ABO incompatible transplantation, paired kidney exchange, and altruistic donor programs. His work with patients in these programs has been featured on the Today Show, Good Morning America, The CBS and NBC Evening News, CNN, The Discovery Channel, and in USA Today, The New York Times and The Washington Post. He was part of the team that performed the world's first live donor kidney removal using minimally invasive techniques. He led the team that performed the first triple swap kidney transplant. He is considered a world's expert on kidney transplantation for highly-sensitized and ABO incompatible patients. His other clinical interests include the use of expanded criteria donors and pulsatile perfusion pumping to preserve and rescue these organs. Dr. Montgomery is the principle investigator on a Health and Human Services grant to study methods of optimizing utilization of kidneys from deceased donors. He runs an NIH funded laboratory which is focused on the mechanisms underlying the immunomodulatory effect of plasmapheresis, as well as gene and cell based therapies for ameliorating ischemia/reperfusion injury to transplanted organs.

Office Phone: 
(410) 955-8665


In our next webinar, we’ll analyze Biden’s COVID-19 strategy in the first 100 days — and the huge obstacles the new federal effort must confront. We’ll also look at how Biden plans to address the economic devastation wrought by the pandemic, with a focus on women and vulnerable families. Sign-up here!


Follow Us



CHJ Icon